Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Huge rotating structure of galaxies and dark matter is detected - 2Pleasant Cycle Courses All over the Planet
- 3The Drone Video of the Year is stunning – you've not seen Namibia like this
- 4Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- 5NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- 6 Solid Moving Administrations for a Calm Movement
- FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access
- Brilliant and Gleaming: Excellence and Skincare Practices
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- How mountain terraces have helped Indigenous peoples live with climate uncertainty
- NASA set to launch Artemis 2 moon mission today, the 1st crewed lunar flight since 1972
- Figure out How to Augment Eco-friendliness in Your Volvo XC40
- Moldova says Russian drones violated airspace
